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109Interruption of spinal cord microglial signaling by
alpha-2 agonist dexmedetomidine in a murine
model of delayed paraplegia
Marshall T. Bell, MD,a Viktor A. Agoston, MD,a Kirsten A. Freeman, MD,a Ferenc Puskas, MD, PhD,b
Paco S. Herson, PhD,b Joshua Mares, BS,a David A. Fullerton, MD,a and T. Brett Reece, MD,a Denver, Colo
Background: Despite investigation into preventable pharmacologic adjuncts, paraplegia continues to complicate thor-
acoabdominal aortic interventions. The alpha 2a adrenergic receptor agonist, dexmedetomidine, has been shown to
preserve neurologic function and neuronal viability in a murine model of spinal cord ischemia reperfusion, although the
mechanism remains elusive. We hypothesize that dexmedetomidine will blunt postischemic inﬂammation in vivo
following thoracic aortic occlusion with in vitro demonstration of microglial inhibition following lipopolysaccharide
(LPS) stimulation.
Methods: Adult male C57BL/6 mice underwent 4 minutes of aortic occlusion. Mice received 25 mg/kg intraperitoneal
dexmedetomidine (n [ 8) or 0.9% normal saline (n [ 7) at reperfusion and 12-hour intervals postoperatively until 48
hours. Additionally, sham mice (n[ 3), which had aortic arch exposed with no occlusion, were included for comparison.
Functional scoring was done at 6 hours following surgery and 12-hour intervals until 60 hours when spinal cords were
removed and examined for neuronal viability and cytokine production. Additional analysis of microglia activation was
done in 12 hours following surgery. Age- and sex-matched mice had spinal cord removed for microglial isolation culture.
Cells were grown to conﬂuence and stimulated with toll-like receptor-4 agonist LPS 100 ng/mL in presence of dex-
medetomidine or vehicle control for 24 hours. Microglia and media were then removed for analysis of protein expression.
Results: Dexmedetomidine treatment at reperfusion signiﬁcantly preserved neurologic function with mice in treatment
group having a Basso Score of 6.3 in comparison to 2.3 in ischemic control group. Treatment was associated with
a signiﬁcant reduction in microglia activation and in interleukin-6 production. Microglial cells in isolation when stim-
ulated with LPS had an increased production of proinﬂammatory cytokines and markers of activation. Treatment with
dexmedetomidine signiﬁcantly attenuated microglial activation and proinﬂammatory cytokine production in vitro with
a greater than twofold reduction in tumor necrosis factor-a.
Conclusions: Alpha 2a agonist, dexmedetomidine treatment at reperfusion preserved neurologic function and neuronal
viability. Furthermore, dexmedetomidine treatment resulted in an attenuation of microglial activation and proin-
ﬂammatory cytokine production both in vivo and in vitro following LPS stimulation. This ﬁnding lends insight into the
mechanism of paralysis following thoracic aortic interventions and may guide future pharmacologic targets for attenu-
ating spinal cord ischemia and reperfusion. (J Vasc Surg 2014;59:1090-7.)
Clinical Relevance:Despite the evolutionof surgical techniques, paraplegia continues to complicate aortic interventions.We
have previously shown that pre- and postoperative administration of dexmedetomidine, a commonly used sedation agent,
provides signiﬁcant neuroprotection in amurinemodel of spinal cord ischemia-reperfusion.Althoughdexmedetomidinehas
shown protection in multiple tissue beds, its mechanism of protection remains highly debated. In our model of spinal cord
ischemia-reperfusion, dexmedetomidine exerts signiﬁcant anti-inﬂammatory effects in vivo when given postoperatively and
implicates dexmedetomidine’s anti-inﬂammatory effects on the resident macrophages in the central nervous system.Delayed, progressive paraplegia remains a signiﬁcant
complication of thoracoabdominal aortic interventions.1
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0major contributors to secondary injury and the develop-
ment of delayed paraplegia.2 The role of resident macro-
phages in exacerbation of tissue injury following ischemia
has been demonstrated in the central nervous system
(CNS) as well as other tissue beds.3,4 Pharmacologic
adjuncts to attenuate the postischemic inﬂammatory
sequelae have been a long sought after and a logical target
for reducing the incidence of delayed paraplegia, yet no
current options are available.
Microglia, the resident macrophages in the CNS,
produce both beneﬁcial and toxic effects.5 Spinal cord
injury induces a rapid change in microglial morphology,
gene expression, and functional behavior.6 Once activated,
microglia can produce a host of neurotoxic mediators such
as interleukin (IL)-1b, tumor necrosis factor (TNF)-a, and
nitric oxide.5 Stimulation of microglial with bacterial
Table. Basso Mouse Scale for locomotion
Score Operational deﬁnition (Basso et al13)
0 No ankle movement
1 Slight ankle movement
2 Extensive ankle movement
3 Plantar placing of the paw with or without weight support,
or occasional, frequent -OR-
Consistent dorsal stepping but no plantar stepping
4 Occasional plantar stepping
5 Frequent or consistent plantar stepping, no coordination
-OR-
Frequent or consistent plantar stepping, some
coordination, paws rotated at initial contact and lift off
6 Frequent or consistent plantar stepping, some
coordination, paws parallel at initial contact -OR-
Frequent or consistent plantar stepping, mostly
coordinated, paws rotated at initial contact and lift off
7 Frequent or consistent plantar stepping, mostly
coordinated, paws parallel (P) at initial contact and
rotated (R) at lift off (P/R) -OR-
Frequent or consistent plantar stepping, mostly
coordinated, paws parallel at initial contact and lift off
(P/P), and severe trunk instability
8 Frequent or consistent plantar stepping, mostly
coordinated, paws parallel at initial contact and lift off
(P/P), and mild trunk instability -OR-
Frequent or consistent plantar stepping, mostly
coordinated, paws parallel at initial contact and lift off
(P/P), and normal trunk stability and tail down or up
and down
9 Frequent or consistent plantar stepping, mostly
coordinated, paws parallel at initial contact and lift off
(P/P), and normal trunk stability and tail always up
Fig 1. Hindlimb function, as characterized by the Basso Mouse
Score, demonstrated a progressive decline in function of ischemia-
reperfusion (IR) controls. Mice treated with dexmedetomidine
(Dex) had a similar initial decline; however, their function stabi-
lized and was signiﬁcantly higher (*P < .05) than IR controls from
36 to 60 hours of reperfusion.
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transform into a neurotoxic phenotype seen acutely
following ischemia.7-9
Dexmedetomidine is a highly selective a-2a adrenore-
ceptor agonist with well-documented neuroprotective
effects.10,11 Many have postulated that the protective
effects are secondary to its anti-inﬂammatory characteris-
tics, however, these remain ill-deﬁned. We hypothesize
that dexmedetomidine will blunt postischemic inﬂamma-
tion in vivo following thoracic aortic occlusion with
in vitro demonstration of an inhibition of microglial activa-
tion and cytokine production following LPS stimulation.
METHODS
Animal procedures. All experiments were approved
by the Animal Care and Use Committee at the University
of Colorado, and this investigation conformed to the
Guide for the Care and Use of Laboratory Animals pub-
lished by the National Institute of Health (www.nap.
edu/catalog/5140.html).
Ischemia-reperfusion(IR)surgery. Eighteen C57BL/
6 male mice 12 to 20 weeks were obtained from Jackson
Laboratories (Sacramento, Calif). Using 2% isoﬂurane expo-
sure of the thoracic aortic arch and subclavian artery were
obtained through a cervicothoracic approach.12 The aortic
arch and subclavian artery were then occluded with vascularclamps placed under direct visualization. Occlusion was
conﬁrmed by a laser Doppler monitor (Moor Instruments,
Wilmington, Del) over the left femoral artery and main-
tained for 4 minutes. A 90% decrease in distal aortic ﬂow was
present in all mice. Intraoperative body temperature was
maintained at 36.5 6 0.5C using rectal temperature probe
and automatic temperature adjusting bed (Vestavia Scien-
tiﬁc, Birmingham, Ala).
Animals in the treatment group (n ¼ 8) received intra-
peritoneal 25 mg/kg dexmedetomidine, based on previous
studies,4 30 minutes following aortic occlusion and at 12-
hour intervals postoperatively. IR controls (n ¼ 7) received
equivalent amounts of 0.9% at the points as speciﬁed above.
Sham mice (n ¼ 3) had the aortic arch exposed through
the same procedure but no aortic cross clamping. All
animals were sacriﬁced at 60 hours after surgery, and their
spinal cords were harvested for analysis.
Functional assessment. Neurologic function was
quantiﬁed at 6, 12, 24, 36, 48, and 60 hours using Basso
Mouse Scale for locomotion (Table)13 with values
ranging from 0 for complete lower extremity paralysis to
9 for normal function.
Tissue procession. Following 60 hours of reperfusion,
all animals were sacriﬁced and vertebral columns were
removed en bloc from T8-L3. The spinal cord was
removed from the vertebral column by injection of phos-
phate-buffered saline (PBS; pH 7.4) into the spinal column
and transferred to 4% formalin for 24 hours. Following
ﬁxation, tissue was embedded in parafﬁn and stained with
hematoxylin and eosin.
Spinal cords intended for cytokine analysis were
removed at 60 hours as above then ﬂash-frozen using
2-methylbutane (Fisher Scientiﬁc, Fair Lawn, NJ) and
dry ice and stored at 80C. Samples were then thawed
to 4C, weighed and homogenized using 10 mL/mg of
ethylenediaminetetra-acetic acid-free, complete lysis-M
buffer (Roche Diagnostics Corporation, Indianapolis,
Fig 2. Representative slices of spinal cords following sham or IR surgery. Images are shown at original
magniﬁcation40 with images in the box at original magniﬁcation. Mice treated with dexmedetomidine (IRþDex) had
more normal appearing anterior horn motor neurons with less gray-white matter disruption and fewer inﬂammatory
inﬁltrates compared with ischemia-reperfusion (IR) controls. Normal appearing anterior horn neurons were quantiﬁed
by a blinded observer. All mice undergoing IR surgery had signiﬁcantly less anterior horn neurons (þþP< .05) compared
with compared with sham mice. Comparison of mice that underwent IR surgery revealed that mice treated with dex-
medetomidine (IRþDex) had a signiﬁcantly higher quantity of normal anterior horn neurons (*P < .05).
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using NanoDrop ND-100 Spectrophotometer (Thermo
Scientiﬁc, Wilmington, Del).
Histologic analysis and neuronal quantiﬁcation.
Sections and examined for cyto-architectural characteristics
following hematoxylin and eosin. Neurons within the
anterior horn that contained prominent nucleoli and loose
chromatin were considered normal. Neuronal viability was
quantiﬁed by a blinded observer and recorded as neurons
per microscopic ﬁeld.
Immunoﬂuorescence. Twelve hours following IR
surgery, six mice, three treatment, and three IR controls
had spinal cords removed and ﬁxed as described above.
Following ﬁxation, samples were placed in Tissue Freezing
Medium (Electron Microscopy Sciences, Hatﬁeld, Pa)
at 80C. Cryosections (10-mm thick) were cut and
collected on poly-l-lysine-coated slides. Slides were
treated with a mixture of 30% acetone and 70% methanol
for 10 minutes then blocked with 10% normal donkey
serum for 45 minutes. Primary incubation occurred over-
night with a polyclonal rabbit anti-mouse ED-1 (Santa
Cruz Biotechnology, Santa Cruz, Calif) at a 1:150 dilution
and immune-matched IgG (5 mg/mL) containing 1%
bovine serum albumin (BSA). Secondary incubation was
perfumed for 1 hour with Cy3-conjugated matched IgG
(Jackson Laboratories, Inc, West Grove, Pa) at 1:150dilution with PBS containing 1% BSA. Bis-benzimide was
used (40,6-diamidino-2-phenylindole, imaged on the blue
channel) to stain nuclei and wheat-germ agglutinin to stain
cell membranes (labeled with Alexa 488 and imaged on the
green channel). ED-1 was imaged using the red Cy3
channel. Microscopic observation and photography were
performed by Leica DMRXA confocal microscope (Leica
Mikroskopie und Systeme GmbH, Wetzlar, Germany).
Microglial isolation. Male mice 12 to 20 weeks had
vertebral column removed en bloc. Spinal cords were cut
longitudinally and transferred to cold, Hibernate A (Brain
Bits, LLC, Springﬁeld, Ill) with glutamax 0.5 mM and
10% fetal bovine serum (Invitrogen, Grand Island, NY).
Sections were then enzymatically digested for 75 minutes
in papain at 2 mg/mL (Worthington Inc, Lakewood,
NJ) at 37C in an orbital shaker at a at 175 rpm. Tissue
was then allowed to settle to 2 minutes, and papain solu-
tion was replaced with warm hibernate A (Invitrogen)
B27 with glutamax (0.5 mM). Tissue was triturated 10
times for 45 seconds.
After allowing the tissue to settle, the upper 2 mL of
supernatant was collected to a tube containing warm hiber-
nate A B27 with glutamax (0.5 mM). The sediments were
then resuspended and triturated again and supernatants
were combined after four sets of trituration. The tissue was
triturated in 8 mL of fresh hibernate A with glutamine
Fig 3. Microglia activation 12 hours following IR surgery was depicted by immunoﬂuorescence of spinal cords
incubation with anti-ED-1 on Cy3 channel (red) at 40 magniﬁcation. Nuclei are resented by 40,6-diamidino-
2-phenylindole stain in blue with wheat germ agglutinin conjugated ﬂourescein isothiocyanate staining in green for
cytoplasm. All tissue incubated with anti-ED-1anti-body had a signiﬁcant increase in the area of positive stain compared
with IgG controls (*P < .05). Mice treated with dexmedetomidine (IRþDex) had a signiﬁcant reduction in ED-1
positive microglia compared with ischemia-reperfusion (IR) controls (þþP < .05). Quantiﬁcation for the area of
tissue staining positive for anti-ED-1 antibody was performed and shown.
Fig 4. Concentrations of cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-a in spinal cord homogenates
at 60 hours of reperfusion are represented. While TNF-a did a show slight decrease with dexmedetomidine treatment,
it did not reach statistical signiﬁcance. Treatment with dexmedetomidine (IRþDex), however, did result in a signiﬁcant
in concentration of IL-6 compared with ischemia-reperfusion (IR) controls (*P < .05).
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a 4-mL step gradient (Optipep diluted 0.505:0.495 [v/v])
with hibernate Aeglutamine 0.5 mMeB27; 15%, 20%,
25%, and 35% (v/v) in hibernate Aeglutamine 0.5
mMeB27 followed by centrifugation for 25 minutes, using1800 rpm, at 24C. The top 10 mL of the supernatant was
aspirated. The bottom 1 mL was collected and diluted in
5 mL hibernate AeB27, and centrifugation was repeated
at 1000 g for 5 minutes. The pellet was then resuspended
in hibernate AeB27, and centrifuged again at 1000 g for
Fig 5. Following stimulation with lipopolysaccharide (LPS)
microglia in both groups had a signiﬁcant upregulation of activa-
tion marker ED-1 (*P > .05) compared with controls. Dexme-
detomidine treatment (LPSþDex) signiﬁcantly reduced the
expression of activation marker ED-1 compared with controls
(LPS) (þþP < .05).
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medium with 20% fetal bovine serum, high-glucose Dulbec-
co’s modiﬁed Eagle’s medium (Invitrogen) with glutaGro
and Na-pyruvate, penicillin-streptomycin then plated in
poly-D-lysine coated wells.
LPS stimulation. Isolated cells were matured for at
least 10 days to obtain conﬂuence. Media was then
replaced with serum free media for 12 hours followed by
incubation with LPS E coli 0111:B4 (InvivoGen, San
Diego, Calif) 100 ng/mL based on previous studies.14
Dexmedetomidine was added to media at a concentration
of 10 mM prior to induction.15 Media was collected
following 24 hours of treatment for analysis of protein
expression.
Cytokine quantiﬁcation. Cytokines were quantiﬁed
from spinal cord homogenate 60 hours following surgery
or microglial media 24 hours following LPS stimulation
using enzyme-linked immunosorbent assay (R & D
Systems, Minneapolis, Minn) performed according to the
manufacturer’s instructions. Absorbance of standards and
samples were determined spectrophotometrically at 595
nm using a microplate reader (Bio-Rad, Hercules, Calif).
Results were plotted against the linear portion of the
standard curve, and the protein concentration of each
sample was expressed as pg/mL of sample.Immunoblotting. Microglia cells were lysed with
M-PER mammalian protein extraction reagent (Fisher
Scientiﬁc, Pittsburg, Pa). Protein extracts were placed
in 4 laemmli sample buffer with b-mercaptoethanol and
boiled for 10 minutes at 100C, loaded into a 10-well
4%-20% gradient ready gels (Bio-Rad), and run at 160 V
for 50 minutes. The gels were transferred to nitrocellulose
membranes at 100 V for 60 minutes, and then cross-linked
using a UV Stratalinker (Stratagene, La Jolla, Calif). The
membranes were blocked in 5% dry milk in 0.1% Tween in
PBS (T-PBS). The blocked membranes were incubated
with primary antibody overnight at 4C (diluted to 1:1000
5% BSA in 0.1% T-PBS). Secondary incubated in appro-
priate horseradish peroxidase-conjugated antibodies
diluted to 1:5000 in 5% BSA in 0.1% T-PBS then occurred
for 1 hour at room temperature. SuperSignal West Dura
chemiluminescent substrate (Thermo Scientiﬁc, Rockford,
Ill) was used for 5 minutes. Membranes were visualized by
Chemidoc Hi Sensitivity (Bio-Rad) scanner. Mean density
values of bands were quantiﬁed by Quantity One software
(Bio-Rad).
Statistical analysis. Statistical analysis was performed
using analysis of variance with Fisher least signiﬁcant differ-
ence post-hoc test (StatView; SAS Institute Inc, Cary,
NC). Data are presented as mean 6 standard error. A
P value of <.05 was considered signiﬁcant for all statistical
comparisons.
RESULTS
Neurologic function. Hindlimb was function
recorded using Basso Mouse Score (Fig 1). All mice that
underwent IR surgery had some progressive, functional
decline. Mice treated with dexmedetomidine (IRþDex)
did not have the same progression or severity as IR
controls. A statistically signiﬁcance was observed (P < .05)
between treatment and control groups at 36 to 60 hours
(Fig 1).
Histology and neuronal viability. Mice subjected to
IR surgery that did not receive treatment (IR) exhibited
poor gray-white matter differentiation and increased
inﬂammatory inﬁltration compared with treated (IRþDex)
or sham mice (Fig 2). The quantity of normal appearing
anterior horn neurons was also signiﬁcantly decreased in all
mice that underwent IR surgery compared with mice
subjected only to sham surgery. Mice that received dex-
medetomidine treatment postoperatively had signiﬁcantly
higher normal appearing anterior horn neurons compared
with IR controls.
Spinal cord microglial activation. Spinal cords from
mice 12 hours following IR surgery were assessed for
microglial activation by ED-1, a speciﬁc marker of activa-
tion. Mice treated with dexmedetomidine at reperfusion
had a signiﬁcant reduction of ED-1 expression compared
with mice in ischemic control groups (Fig 3).
Spinal cord cytokine expression. Spinal cord hom-
ogenate following IR or sham surgery was compared for
cytokine production at 60 hours. Mice treated with dexme-
detomidine (IRþDex) had a signiﬁcant reduction in the
Fig 6. Microglial expression of cytokines tumor necrosis factor (TNF)-a and interleukin (IL)-6 were signiﬁcantly
increased following lipopolysaccharide (LPS) stimulation (*P > .05) compared with controls. Treatment with dex-
medetomidine (LPSþDex) signiﬁcantly reduced the expression of both cytokines (þþP < .05) compared with LPS
treatment alone (LPS).
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a expression was reduced in treated mice compared with
IR controls, however, this value did not reach statistical
signiﬁcance (Fig 4).
Microglial activation in isolation. Exposure of cells
to LPS resulted in a signiﬁcant increase in microglial activa-
tion compared with controls. Treatment with dexmedeto-
midine (LPSþDex) resulted in a signiﬁcant reduction in
microglial activation after 24 hours of exposure to LPS
(Fig 5).
Microglial cytokine production. Expression of the
neurotoxic cytokines TNF-a and IL-6 was signiﬁcantly
elevated following exposure to LPS for 24 hours. Treat-
ment of microglia with dexmedetomidine prior to LPS
stimulation resulted in a signiﬁcant attenuation of cytokine
production (Fig 6).
CONCLUSIONS
Despite the evolution of surgical adjuncts and increased
understanding of spinal cord ischemia-reperfusion injury,
paraplegia remains a signiﬁcant complication of thoracoab-
dominal aortic interventions. Patients with this injury
exhibit either an immediate postoperative paralysis or
develop a delayed injury following the surgery, with the
latter becoming more prominent.1 Delayed paraplegia,
while equally as devastating, lends hope for the develop-
ment of agents to reduce this complication. Investigation
using our delayed paraplegia model12 intends to create
a pharmacologic adjunct to attenuation of this injury.
While immediate postoperative paraplegia directly
correlates with duration of ischemia, delayed paraplegia
from secondary injury appears to be more complex. Extrap-
olation of knowledge from stroke, ischemic, and traumatic
models of spinal cord injury has given potential insight intothese secondary neuroinﬂammatory sequelae and their
contribution to progressive injury in the CNS.16-18 In
murine studies of loss of hindlimb motor function
following thoracic aortic occlusion occurs in parallel with
progressive production of inﬂammatory mediators.19
Our group has previously shown that combined treat-
ment with dexmedetomidine before and after injury infers
signiﬁcant neuroprotection following temporary thoracic
aortic occlusion.20 While this neuroprotective effect in
the spinal cord was consistent with those previous reported
in the CNS10,21 and other tissue beds3,22 dexmedetomi-
dine protective effect remains controversial.
Animal models and clinical trials have yielded consider-
able evidence that dexmedetomidine has signiﬁcant anti-
inﬂammatory properties. Rodent models of sepsis have
shown than dexmedetomidine signiﬁcantly reduces morality
thought to be secondary to attenuation proinﬂammatory
cytokine production.23 Additionally, dexmedetomidine
attenuated expressionof proinﬂammatorymarkers in patients
undergoing laparoscopic surgery.24 Treatment was also asso-
ciated with a reduction in length of ventilation and mortality
in septic patients compared with standard sedation.25
In the current model of delayed paraplegia, even in the
absence of preoperative treatment, dexmedetomidine was
effective in preserving hindlimb function and neuronal
viability. Furthermore, treatment was associated with an
attenuation of microglial activation and cytokine produc-
tion. Though these ﬁndings were not as signiﬁcant as previ-
ously seen with pre- and postoperative administration,
a protective effect was still evident.
While the reason for better protection with pretreat-
ment remains unknown, it is likely multifactorial. One
possibility is microglia activation prior to administration
of dexmedetomidine could result in only a partial reduction
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produce a host of other beneﬁcial effects including modiﬁ-
cations in neuronal ischemic tolerance15 and reduced exci-
totoxicity.26 The current ﬁndings are consistent with other
models of spinal cord injury that have shown a reduc-
tion in proinﬂammatory cytokines following compressive
injuries27 and an attenuation of microglial activation in
arthritic models.28 However, these studies do not directly
implicate dexmedetomidine’s effect on microglia or subse-
quent neuroinﬂammation.
Microglia, the resident immune cells in the CNS, can
produce a host of beneﬁcial and toxic responses. Postinju-
rious microglial neurotoxicity has been shown by various
models throughout the CNS. Systemic treatment with
clodronate, an agent which depletes cells of macrophage
lineage, protected the spinal cord from following traumatic
injury.29 Additionally, studies of cultured neuron and
microglia have shown an ampliﬁcation of neuronal injury
when placed in co-cultures compared with isolation.30
It is now widely accepted that microglia can become
activated into distinctly different phenotypes (denoted
M1 and M2), which are either neurotoxic (M1) or neuro-
protective (M2).9 In the acute phase, the neurotoxic
phenotype predominates.31 Stimulation of microglial with
LPS rapidly incites activation to the M1, neurotoxic,
phenotype. While LPS is not the speciﬁc agonist in spinal
cord injury following ischemia, it closely mimics other
cellular signals such as heat shock proteins32 or ganglio-
sides33 released from injured neurons.
To demonstrate the impact of dexmedetomidine on
microglial signaling, spinal cord microglia were cultured
in isolation and stimulated with LPS. Stimulation of micro-
glia with LPS resulted in signiﬁcant microglial activation
and production cytokines, TNF-a, and IL-6. Treatment
of microglia cultures with dexmedetomidine prior to LPS
stimulation inferred a signiﬁcant reduction in the expres-
sion of microglial activation marker ED-1 as well signiﬁcant
attenuation of cytokines.
Together this collection of data yields further evidence
that the a-2 agonist dexmedetomidine exerts signiﬁcant
anti-inﬂammatory effects both in vivo and in vitro.
Furthermore, this reduction of microglial responses
provides a potential mechanism for dexmedetomidine’s
neuroprotective effect and could one day be a potential
target to reduce the incidence of paraplegia following
thoracic aortic interventions.AUTHOR CONTRIBUTIONS
Conception and design: MB, VA, FP, KF, PH, DF, JM,
TR
Analysis and interpretation: MB, VA, FP, KF, PH, DF, JM,
TR
Data collection: MB, VA, JM, KF, TR
Writing the article: MB, VA, FP, KF, JM, TR
Critical revision of the article: MB, VA, DF, PH, TR
Final approval of the article: MB, VA, FP, KF, PH, JM,
DF, TRStatistical analysis: MB, VA, KF, FP, TR
Obtained funding: FP, PH, DF, TR
Overall responsibility: MBREFERENCES
1. Conrad MF, Ye JY, Chung TK, Davison JK, Cambria RP. Spinal cord
complications after thoracic aortic surgery: long-term survival and
functional status varies with deﬁcit severity. J Vasc Surg 2008;48:
47-53.
2. Fleming JC, Norenberg MD, Ramsay DA, Dekaban GA, Marcillo AE,
Saenz AD, et al. The cellular inﬂammatory response in human spinal
cords after injury. Brain 2006;129:3249-69.
3. Okada H, Kurita T, Mochizuki T, Morita K, Sato S. The car-
dioprotective effect of dexmedetomidine on global ischemia in isolated
rat hearts. Resuscitation 2007;74:538-45.
4. Gu J, Chen J, Xia P, Tao G, Zhao H, Ma D. Dexmedetomidine
attenuates remote lung injury induced by renal ischemia-reperfusion in
mice. Acta Anaesthesiol Scand 2011;55:1272-8.
5. Block ML, Zecca L, Hong J-S. Microglia-mediated neurotoxicity:
uncovering the molecular mechanisms. Nat Rev Neurosci 2007;8:
57-69.
6. Stirling DP, Yong VW. Dynamics of the inﬂammatory response after
murine spinal cord injury revealed by ﬂow cytometry. J Neurosci Res
2008;86:1944-58.
7. Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg P,
et al. Activation of innate immunity in the CNS triggers neuro-
degeneration through a Toll-like receptor 4-dependent pathway. Proc
Natl Acad Sci U S A 2003;100:8514-9.
8. Kawai T, Akira S. Signaling to NF-kB by toll-like receptors. Trends
Mol Med 2007;13:460-9.
9. David S, Kroner A. Repertoire of microglial and macrophage responses
after spinal cord injury. Neuroscience 2011;12:388-99.
10. Sanders RD, Sun P, Patel S, Li M, Maze M, Ma D. Dexmedetomidine
provides cortical neuroprotection: impact on anesthetic-induced neu-
roapoptosis in the rat developing brain. Acta Anaesthesiol Scand
2010;54:710-6.
11. Ma D, Rajakumaraswamy N, Maze M. alpha2-Adrenoceptor agonists:
shedding light on neuroprotection? Br Med Bull 2004;71:77-92.
12. Smith PD, Puskas F, Meng X, Cho D, Cleveland JC, Weyant MJ, et al.
Ischemic dose-response in the spinal cord: both immediate and delayed
paraplegia. J Surg Res 2011;7:1-7.
13. Basso DM, Fisher LC, Anderson AJ, Jakeman LB, McTigue DM,
Popovich PG. Basso Mouse Scale for locomotion detects differences in
recovery after spinal cord injury in ﬁve common mouse strains.
J Neurotrauma 2006;23:635-59.
14. Jiang SX, Slinn J, Aylsworth A, Hou ST. Vimentin participates in
microglia activation and neurotoxicity in cerebral ischemia.
J Neurochem 2012;122:764-74.
15. Zhang F, Ding T, Yu L, Zhong Y, Dai H, Yan M. Dexmedetomidine
protects against oxygen-glucose deprivation-induced injury through
the I2 imidazoline receptor-PI3K/AKT pathway in rat C6 glioma cells.
J Pharm Pharmacol 2012;64:120-7.
16. Harukuni I, Bhardwaj A. Mechanisms of brain injury after global
cerebral ischemia. Neurol Clin 2006;24:1-21.
17. Papakostas JC, Matsagas MI, Toumpoulis IK, Malamou-Mitsi VD,
Pappa LS, Gkrepi C, et al. Evolution of spinal cord injury in a porcine
model of prolonged aortic occlusion. J Surg Res 2006;13:159-66.
18. Kwon BK, Tetzlaff W, Grauer JN, Beiner J, Vaccaro AR. Pathophysi-
ology and pharmacologic treatment of acute spinal cord injury. Spine J
2004;4:451-64.
19. Smith PD, Puskas F, Meng X, Lee JH, Cleveland JC, Weyant MJ, et al.
The evolution of chemokine release supports a bimodal mechanism of
spinal cord ischemia and reperfusion injury. Circulation 2012;126(11
Suppl 1):S110-7.
20. Bell MT, Puskas F, Smith PD, Agoston VA, Fullerton DA, Meng X,
et al. Attenuation of spinal cord ischemia-reperfusion injury by speciﬁc
a-2a receptor activation with dexmedetomidine. J Vasc Surg 2012;56:
1398-402.
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 4 Bell et al 109721. Ma D, Hossain M, Rajakumaraswamy N, Arshad M, Sanders RD,
Franks NP, et al. Dexmedetomidine produces its neuroprotective effect
via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol 2004;502:
87-97.
22. Kocoglu H, Ozturk H, Ozturk H, Yilmaz F, Gulcu N. Effect of dex-
medetomidine on ischemia-reperfusion injury in rat kidney: a histo-
pathologic study. Ren Fail 2009;31:70-4.
23. Taniguchi T, Kurita A, Kobayashi K, Yamamoto K, Inaba H. Dose- and
time-related effects of dexmedetomidine on mortality and inﬂammatory
responses to endotoxin induced shock in rats. J Anesth 2008;22:221-8.
24. Kang S-H, Kim Y-S, Hong T-H, Chae M-S, Cho M-L, Her Y-M, et al.
Effects of dexmedetomidine on inﬂammatory responses in patients
undergoing laparoscopic cholecystectomy. Acta Anaesthesiol Scand
2012:1-8.
25. Pandharipande PP, Sanders RD, Girard TD, McGrane S,
Thompson JL, Shintani AK, et al. Effect of dexmedetomidine versus
lorazepam on outcome in patients with sepsis: an a priori-designed
analysis of the MENDS randomized controlled trial. Crit Care
2010;14:R38.
26. Chiu K-M, Lin T-Y, Lu C-W, Wang S-J. Inhibitory effect of glutamate
release from rat cerebrocortical nerve terminals by a2 adrenoceptor
agonist dexmedetomidine. Eur J Pharmacol 2011;670:137-47.
27. Can M, Gul S, Bektas S, Hanci V, Acikgoz S. Effects of dexmedeto-
midine or methylprednisolone on inﬂammatory responses in spinal cord
injury. Acta Anaesthesiol Scand 2009;53:1068-72.28. Xu B, Zhang W-S, Yang J-L, Lû N, Deng X-M, Xu H, et al. Evidence
for suppression of spinal glial activation by dexmedetomidine in a rat
model of monoarthritis. Clin Exp Pharmacol Physiol 2010;37:
158-66.
29. Popovich PG, Guan Z, Wei P, Huitinga I, Van Rooijen N, Stokes BT.
Depletion of hematogenous macrophages promotes partial hindlimb
recovery and neuroanatomical repair after experimental spinal cord
injury. Exp Neurol 1999;158:351-65.
30. Filipovic R, Zecevic N. Neuroprotective role of minocycline in co-
cultures of human fetal neurons and microglia. Exp Neurol
2008;211:41-51.
31. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ,
Popovich PG. Identiﬁcation of two distinct macrophage subsets with
divergent effects causing either neurotoxicity or regeneration in the
injured mouse spinal cord. J Neurosci 2009;29:13435-44.
32. Lehnardt S, Schott E, Trimbuch T, Laubisch D, Krueger C,
Wulczyn G, et al. A vicious cycle involving release of heat shock protein
60 from injured cells and activation of toll-like receptor 4 mediates
neurodegeneration in the CNS. J Neurosci 2008;28:2320-31.
33. Jou I, Lee JH, Park SY, Yoon HJ, Joe E-H, Park EJ. Gangliosides
trigger inﬂammatory responses via TLR4 in brain glia. Am J Pathol
2006;168:1619-30.Submitted Jan 29, 2013; accepted Apr 19, 2013.
